Such examples include UCN-01, a nonselective PDK1 inhibitor, which has shown promise in combination therapy with irinotecan for treatment of metastatic triple-negative breast cancer (Wang et al., 2022). This evidence concerns the gene PDK1 and triple-negative breast carcinoma.